Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Publication

Article

June 9, 2006

CURE

Summer 2006
Volume5
Issue 2

Inherited Syndromes Link Cancers

Author(s):

Elizabeth Whittington

In addition to treatment-related risks, some survivors discover they have a genetic syndrome that may lead to a second cancer.

In addition to treatment-related risks, some survivors discover they have a genetic syndrome that may lead to a second cancer. Scientists are finding that it may not be where cancer strikes that’s important, but what’s causing it in the first place.

The most well-known genetic mutations, BRCA1 and BRCA2, can signify an increased risk of developing not only breast cancer in men and women, but also ovarian cancer. Coupled with a 55 to 85 percent lifetime risk for breast cancer, individuals with the BRCA1 mutation have a 40 to 60 percent lifetime risk for developing a second breast cancer.

Li-Fraumeni syndrome, a rare genetic disorder often caused by a mutated p53 gene, can increase the risk for breast cancer, sarcoma, leukemia, brain tumors and other cancers. Studies have shown that people with the inherited mutation have at least an 85 percent chance of developing cancer during their lifetime. A study of 200 people with inherited Li-Fraumeni syndrome found that 15 percent developed a second cancer, 4 percent had a third cancer and 2 percent had four cancers. Childhood cancer survivors with the syndrome were found to be at highest risk for second cancers.

The inactivation of a tumor-suppressor gene called von Hippel-Lindau (VHL) may cause up to 85 percent of all kidney cancers. A person is born with two copies of every gene, so both VHL genes must be inactive or mutated before tumors form. Patients with one inherited VHL mutation have a much greater likelihood of developing kidney cancer since it only takes a mutation of the second VHL gene for tumors to occur. In addition to kidney cancer, VHL is associated with tumors of the eye, brain, spine and pancreas.

Genetic syndromes only account for 5 percent of all colorectal cancer cases, but hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome, and familial adenomatous polyposis (FAP) dramatically increase the risk. HNPCC is caused by a defect in DNA repair genes, four of which have been identified. Because these genes oversee DNA cell replication, defects can cause other types of cancers, including uterine and ovarian cancer. FAP results from only one mutated gene, but it can increase the risk of developing colorectal cancer to 90 percent by age 45. Thyroid, small bowel and brain cancers have also been noted with this mutation.

For a complete list of cancer screening recommendations, visit www.cancer.org or www.genetichealth.com. To find a genetic counselor in your area, visit the website of the National Society of Genetic Counselors at www.nsgc.org.

Articles in this issue

Glossary
Breast Cancer & MDS
Confronting Death
Nonmelanoma Skin Cancer: Saving Your Skin
Surf & Turf
A Beautiful Day: The Story of a Son's Loss
People & Places
The Blame Game
Running on Empty
Fighting Cancer Together
Cancer as a Legacy
Tips for Preventing Infection
Choosing a Counselor
Message from the Editor-at-Large
Letters from Our Readers

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Image of woman.
Image of man.
Image of Dr. Merrell
The field of radiation oncology has advanced in brain cancer treatment with precise therapeutic approaches including proton and carbon therapy.
Image of Dr. Eng.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Related Content
Advertisement
Image of Patti.
June 12th 2025

Beyond Treatment: How Support Groups Helped Me Embrace My New Normal

Patti McGee
Joining support groups after cancer treatment helped me heal emotionally, connect with others who understood and embrace a new, meaningful normal.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
FDA approves new Brukinsa tablet for five blood cancers: © stock.adobe.com.
June 12th 2025

FDA Approves Brukinsa Tablet For Various Blood Cancers

Spencer Feldman
FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as capsules.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Brenda Denzler is a writer and editor living in North Carolina. She was diagnosed with inflammatory breast cancer in 2009. Catch up on Brenda’s blogs here.
June 10th 2025

A Letter to My 2009 Self, Newly Diagnosed With Breast Cancer

Brenda Denzler
I survived breast cancer and medical trauma, but the road was brutal. Fifteen years later, I’m alive, scarred and still searching for peace.
Dr. Mabel Mardones educates patients on breast cancer updates: © stock.adobe.com.
June 10th 2025

Understanding Breast Cancer Biomarkers Drives Patient Treatment Decisions

Kristie L. Kahl
Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2-negative disease.
Related Content
Advertisement
Image of Patti.
June 12th 2025

Beyond Treatment: How Support Groups Helped Me Embrace My New Normal

Patti McGee
Joining support groups after cancer treatment helped me heal emotionally, connect with others who understood and embrace a new, meaningful normal.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
FDA approves new Brukinsa tablet for five blood cancers: © stock.adobe.com.
June 12th 2025

FDA Approves Brukinsa Tablet For Various Blood Cancers

Spencer Feldman
FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as capsules.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Brenda Denzler is a writer and editor living in North Carolina. She was diagnosed with inflammatory breast cancer in 2009. Catch up on Brenda’s blogs here.
June 10th 2025

A Letter to My 2009 Self, Newly Diagnosed With Breast Cancer

Brenda Denzler
I survived breast cancer and medical trauma, but the road was brutal. Fifteen years later, I’m alive, scarred and still searching for peace.
Dr. Mabel Mardones educates patients on breast cancer updates: © stock.adobe.com.
June 10th 2025

Understanding Breast Cancer Biomarkers Drives Patient Treatment Decisions

Kristie L. Kahl
Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2-negative disease.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.